Attempt to find the threshold of incremental cost-effectiveness ratio for a new drug to accept it in national health insurance
| Project/Area Number |
19590521
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical sociology
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
SHIRAGAMI Makoto Nihon University, 薬学部, 教授 (00339243)
|
|---|
| Research Collaborator |
KURITA Mituru 日本大学, 大学院・薬学研究科・博士前期課程2年
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2007: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 増分費用効果比 / 薬価 / 治療充足度 / 医療保険 / 新医薬品 / 効用値 |
|---|
| Research Abstract |
Considering the notion, prevailing in western countries, that the pharmaceutical should not be reimbursed by health insurance unless its Incremental Cost-effectiveness Ratio (ICER) is less than some pre-decided value, we tried to find the pre-decided value suitable to Japanese system based on the prices of 73 new products in Japan. ICER varied widely from 1200000 yen to 19000000 yen. This indicates that the current rule for calculating pharmaceuticals' price dose not necessarily reflect cost-effectiveness of new pharmaceutical. Reverse correlation was found between ICER for a disease and medical satisfaction. It suggests that ICERs for diseases classified by medical satisfaction can be used as pre-decided values under current price calculating system.
|
Report
(4 results)
Research Products
(4 results)
